Vanguard holds 5.88M Viking Therapeutics shares (NASDAQ: VKTX) in 13G
Rhea-AI Filing Summary
Vanguard Capital Management reported beneficial ownership of 5,877,263 shares of Viking Therapeutics Inc. common stock (5.08% of the class) as of 03/31/2026. The filing shows sole voting power of 864,761 shares and sole dispositive power over 5,877,263 shares, and states these holdings include securities held for Vanguard funds and managed accounts.
Positive
- None.
Negative
- None.
Insights
Large passive holding reported: Vanguard holds 5,877,263 shares (5.08%).
Vanguard Capital Management reports beneficial ownership of 5,877,263 shares with sole voting power of 864,761 shares. The filing attributes ownership to Vanguard funds and affiliated advisory divisions, consistent with pooled-management disclosures under Schedule 13G.
Retention of dispositive power across funds suggests voting and sale decisions rest with Vanguard’s management structures; subsequent filings could show changes in percent ownership or voting power.
Schedule 13G used for passive investors reporting over 5% ownership.
The filing follows Schedule 13G format and cites SEC Release No. 34-39538 language describing aggregation of affiliated voting/dispositive power. It identifies Vanguard Capital Management as reporting on behalf of funds and managed accounts.
Signature is dated 04/30/2026; any material change in holdings would require updated reporting per SEC rules.
Key Figures
Key Terms
Schedule 13G regulatory
sole dispositive power regulatory
beneficially owned financial
Investment Company Act of 1940 regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.